TY - JOUR
T1 - Behavioral and prolactin responses to 5-hydroxytrytophan in rats treated during development with 5,7-dihydroxytryptamine
AU - Breese, George R.
AU - Vogel, Richard A.
AU - Kuhn, Cynthia M.
AU - Mailman, Richard
AU - Mueller, Robert A.
AU - Schanberg, Saul M.
N1 - Funding Information:
This study was supported by USPHS Grants HD-03110, HD-10570, ES-01104 and MH-13688. G.R.B. and S.M.S. are supported by Research Career Development Awards (MH-00013 and MH-04689). The RIA kit for prolactin was kindly provided by the NIAMDD Pituitary Hormone Distribution Program.
PY - 1978/10/27
Y1 - 1978/10/27
N2 - The serotonin precursor, 5-hydroxytryptophan (5-HTP), can induce a behavioral syndrome characterized by rigidity, splayed feet, tremor, head weaving, saliva and forepaw treading. This response to 5-HTP was markedly potentiated in adult rats treated intracisternally with 5,7-dyhydroxytryptamine (5,7-DHT) during development. Prevention of the 5,7-DHT-induced reduction of brain norepinephrine with pargyline or desipramine did not diminish the potentiationof 5-HTP, suggesting that noradrenergic fibers are not contributing to the altered 5-HTP response. It was also found that treatments with 5,7-DHT potentiated the release of prolactin and the disruption of responding in a fixed-ratio operant task induced by 5-HTP. Other experiments indicated that 5,7-DHT treatments potentiated 5-HTP without affecting the action of l-dihydroxyphenylalamine. In addition, administration of the decarboxylase inhibitor, R0-4-4602, at a dose that inhibits enzyme activity in brain, blocked the 5-HTP-induced behavioral syndrome in 5,7-DHT-treated rats, indicating that 5-HTP must be converted to serotonin for 5-HTP to alter behavior. Thus, the present studies indicate that destruction of setonertic fibers during development can produce permanent changes in central serotonergic mechanisms.
AB - The serotonin precursor, 5-hydroxytryptophan (5-HTP), can induce a behavioral syndrome characterized by rigidity, splayed feet, tremor, head weaving, saliva and forepaw treading. This response to 5-HTP was markedly potentiated in adult rats treated intracisternally with 5,7-dyhydroxytryptamine (5,7-DHT) during development. Prevention of the 5,7-DHT-induced reduction of brain norepinephrine with pargyline or desipramine did not diminish the potentiationof 5-HTP, suggesting that noradrenergic fibers are not contributing to the altered 5-HTP response. It was also found that treatments with 5,7-DHT potentiated the release of prolactin and the disruption of responding in a fixed-ratio operant task induced by 5-HTP. Other experiments indicated that 5,7-DHT treatments potentiated 5-HTP without affecting the action of l-dihydroxyphenylalamine. In addition, administration of the decarboxylase inhibitor, R0-4-4602, at a dose that inhibits enzyme activity in brain, blocked the 5-HTP-induced behavioral syndrome in 5,7-DHT-treated rats, indicating that 5-HTP must be converted to serotonin for 5-HTP to alter behavior. Thus, the present studies indicate that destruction of setonertic fibers during development can produce permanent changes in central serotonergic mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=84886637536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886637536&partnerID=8YFLogxK
U2 - 10.1016/0006-8993(78)91022-3
DO - 10.1016/0006-8993(78)91022-3
M3 - Article
C2 - 308387
AN - SCOPUS:84886637536
SN - 0006-8993
VL - 155
SP - 263
EP - 275
JO - Brain research
JF - Brain research
IS - 2
ER -